Short Interest in Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU) Declines By 99.9%

Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU) saw a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 1 shares, a drop of 99.9% from the July 30th total of 884 shares. Based on an average daily volume of 143 shares, the days-to-cover ratio is currently 0.0 days.

Drugs Made in America Acquisition Price Performance

DMAAU stock remained flat at $10.79 during midday trading on Tuesday. Drugs Made in America Acquisition has a 52 week low of $10.30 and a 52 week high of $12.50. The stock’s fifty day moving average is $10.80 and its two-hundred day moving average is $10.70.

Drugs Made in America Acquisition Company Profile

Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.

The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.